OKYO Pharma Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of OKYO Pharma Limited generated cash of -$1,244,983, which is less than the previous year. Cash used in financing activities reached the amount of $6,060,275 last year. Net change in cash is therefore $4,801,722.
Cash Flow
| 2010 | -583K | 13.81M | 685K |
|---|---|---|---|
| 2011 | -815K | 18.13M | -24.99M |
| 2012 | -2.56M | -2.56M | 5.76M |
| 2013 | -2.51M | -4.72M | 5.72M |
| 2016 | -452.91K | -233.23K | 8.6K |
| 2018 | -995.70K | 0 | 0 |
| 2020 | -1.06M | 0 | 774.29K |
| 2021 | -1.24M | -13.57K | 6.06M |
OKYO.L Cash Flow Statement (2010 – 2020)
| 2020 | 2019 | 2017 | 2015 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 189.94K | 481.15K | 3.00M | 4.36M | 10.63M | 9.65M | 17.67M | 21.99M |
Operating activities | ||||||||
Net income | -3.01M | -1.27M | -53.14M | -570.71K | -3.06M | -3.00M | -1.00M | 8.40M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 10.02K | 4.70K | 0 | 0 | 16.08K | 12K | 0 | 0 |
Stock-based compensation expense | 395.29K | 29.48K | 0 | 0 | 876.62K | 516K | 97K | 120K |
| Deferred income tax benefit | 395.29K | 29.48K | 0 | 0 | 876.62K | 516K | 97K | 120K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -1.24M | -1.06M | -995.70K | -452.91K | -2.51M | -2.56M | -815K | -583K |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -316K | -2.65M |
Investments In Property Plant And Equipment | -5.03K | 0 | 0 | -282.54K | -277.62K | -2.19M | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -13.57K | 0 | 0 | -233.23K | -4.72M | -2.56M | 18.13M | 13.81M |
Financing activities | ||||||||
Common Stock Issued | 181.34K | 779.12K | 0 | 0 | 5.61M | 5.25M | 358K | 685K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | -25.35M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 6.06M | 774.29K | 0 | 8.6K | 5.72M | 5.76M | -24.99M | 685K |
Net Change In Cash | 4.80M | -291.21K | -995.70K | -797.12K | -1.20M | 990K | -7.67M | 13.91M |
Cash at end of period | 4.99M | 189.94K | 2.00M | 3.56M | 9.43M | 10.64M | 10.00M | 35.91M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |